10 December 2020 
EMA/CHMP/627792/2020 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Bavencio 
avelumab 
On 10 December 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Bavencio. The marketing authorisation holder for this medicinal product is Merck Europe B.V. 
The CHMP adopted a new indication as follows:2 
Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel 
cell carcinoma (MCC). 
Bavencio is indicated as monotherapy for the first-line maintenance treatment of adult 
patients with locally advanced or metastatic urothelial carcinoma (UC) who are 
progression-free following platinum-based chemotherapy. 
Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients 
with advanced renal cell carcinoma (RCC). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
